.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Baxter
McKesson
Farmers Insurance
Novartis
Chinese Patent Office
McKinsey
Argus Health
Medtronic
Colorcon

Generated: June 24, 2017

DrugPatentWatch Database Preview

Medroxyprogesterone acetate - Generic Drug Details

« Back to Dashboard

What are the generic sources for medroxyprogesterone acetate and what is the scope of medroxyprogesterone acetate patent protection?

Medroxyprogesterone acetate
is the generic ingredient in seven branded drugs marketed by Sandoz Inc, Duramed Pharms Barr, Esi , Pharmacia And Upjohn, Amarin Pharms, Teva Pharms Usa, Barr, Usl Pharma, and Solvay, and is included in fifteen NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Medroxyprogesterone acetate has thirty-eight patent family members in twenty-eight countries.

There are nineteen drug master file entries for medroxyprogesterone acetate. Twenty-three suppliers are listed for this compound.

Summary for Generic Name: medroxyprogesterone acetate

Tradenames:7
Patents:2
Applicants:9
NDAs:15
Drug Master File Entries: see list19
Suppliers / Packagers: see list23
Bulk Api Vendors: see list40
Clinical Trials: see list924
Patent Applications: see list7,121
Therapeutic Class:Hormonal Agents, Stimulant/Replacement/Modifying (Sex Hormones/Modifiers)
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:medroxyprogesterone acetate at DailyMed

Pharmacology for Ingredient: medroxyprogesterone acetate

Ingredient-typeProgesterone Congeners
Drug ClassProgestin
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn
PROVERA
medroxyprogesterone acetate
TABLET;ORAL011839-003Approved Prior to Jan 1, 1982ABRXYesNo► Subscribe► Subscribe
Pharmacia And Upjohn
DEPO-PROVERA
medroxyprogesterone acetate
INJECTABLE;INJECTION012541-003Approved Prior to Jan 1, 1982RXYesYes► Subscribe► Subscribe
Pharmacia And Upjohn
DEPO-SUBQ PROVERA 104
medroxyprogesterone acetate
INJECTABLE;SUBCUTANEOUS021583-001Dec 17, 2004RXYesYes6,495,534► SubscribeY ► Subscribe
Barr
MEDROXYPROGESTERONE ACETATE
medroxyprogesterone acetate
TABLET;ORAL040159-001Aug 9, 1996ABRXNoNo► Subscribe► Subscribe
Pharmacia And Upjohn
DEPO-PROVERA
medroxyprogesterone acetate
INJECTABLE;INJECTION020246-001Oct 29, 1992ABRXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: medroxyprogesterone acetate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pharmacia And Upjohn
DEPO-PROVERA
medroxyprogesterone acetate
INJECTABLE;INJECTION012541-002Approved Prior to Jan 1, 19824,038,389► Subscribe
Pharmacia And Upjohn
DEPO-PROVERA
medroxyprogesterone acetate
INJECTABLE;INJECTION012541-003Approved Prior to Jan 1, 19824,038,389► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: medroxyprogesterone acetate

Country Document Number Estimated Expiration
Japan4205341► Subscribe
Germany60116084► Subscribe
Hong Kong1054194► Subscribe
Hungary229800► Subscribe
Israel165888► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: MEDROXYPROGESTERONE ACETATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0037Belgium► SubscribePRODUCT NAME: OESTROGENES EQUINS CONJUGUES; ACETATE DE MEDROXYPROGESTERONE; NAT. REGISTRATION NO/DATE: NL 19569 19950301; FIRST REGISTRATION: CH - 52647 01 010 19940826
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Chubb
Fish and Richardson
Cipla
Johnson and Johnson
Dow
Novartis
US Department of Justice
Julphar
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot